0001104659-19-037458.txt : 20190625 0001104659-19-037458.hdr.sgml : 20190625 20190625180507 ACCESSION NUMBER: 0001104659-19-037458 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190624 FILED AS OF DATE: 20190625 DATE AS OF CHANGE: 20190625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harrison Seth Loring CENTRAL INDEX KEY: 0001404955 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 19919552 MAIL ADDRESS: STREET 1: 230 PARK AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10169 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 a4.xml 4 X0306 4 2019-06-24 0 0001744659 Akero Therapeutics, Inc. AKRO 0001404955 Harrison Seth Loring C/O AKERO THERAPEUTICS, INC. 170 HARBOR WAY, 3RD FLOOR SOUTH SAN FRANCISCO CA 94080 1 0 1 0 Common Stock 2019-06-24 4 C 0 4228764 A 4228764 I See Footnote Common Stock 2019-06-24 4 C 0 286439 A 4515203 I See Footnote Common Stock 2019-06-24 4 P 0 900000 16 A 5415203 I See Footnote Series A Preferred Stock 2019-06-24 4 C 0 13000000 0 D Common Stock 4228764 0 I See Footnote Series B Preferred Stock 2019-06-24 4 C 0 880568 0 D Common Stock 286439 0 I See Footnote Represents the total number of shares of common stock received by Apple Tree Partners IV, L.P. ("ATP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. Represents the total number of shares of common stock received by ATP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP. On June 24, 2019, ATP purchased 900,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering. /s/ Jonathan Young, as attorney-in-fact 2019-06-25